Inner Logic Raises $11.5M Seed for Medical Device Simulation

Inner Logic, the Baltimore surgical AI company previously known as Semaphor Surgical, has announced an $11.5M seed round to build simulation and data infrastructure for procedural medical devices. General Catalyst and Bison Ventures co-led the financing, with J2VP, Defined, PTX, Valia Ventures, Page One, Alumni Ventures, and Flare participating.

The company is building a virtual testing layer for devices that operate inside the body, from conventional tools such as catheters and heart valves to intelligent and increasingly autonomous surgical systems. Its platform is designed to help manufacturers evaluate device mechanics, generate synthetic data, and produce in silico evidence before advancing further into physical and clinical testing.

The broader signal is not that software is about to replace surgeons or laboratory work. It is that medical devices are becoming more intelligent while the infrastructure used to test them still has to catch up, and Inner Logic wants to build that missing layer.

What Happened

The $11.5M seed financing gives Inner Logic capital to expand its platform and work with manufacturers developing conventional, intelligent, and autonomous procedural systems. Johns Hopkins had previously described the company, then operating as Semaphor Surgical, as having raised more than $11.5M by March 2026, while another portfolio source dates the financing to Fall 2025. July 22, 2026 therefore appears to be the public announcement date rather than necessarily the closing date of the financing.

That distinction matters because funding announcements often compress months of product development, investor diligence, and company execution into a single headline. The more important story is what the capital is intended to build: reusable simulation environments capable of exposing devices to broader anatomical variation, imaging conditions, procedural complexity, and potential failure scenarios before another costly physical iteration begins.

Why Simulation Is Becoming the Infrastructure Layer

Medical device development has an inherently difficult relationship with edge cases. Teams need to understand what happens when anatomy varies, sensors produce noisy data, instruments behave differently than expected, or rare complications emerge, yet those situations cannot be scheduled on demand. Prototypes, cadaver laboratories, animal studies, regulatory review, and clinical evidence remain indispensable, but each comes with limitations in speed, cost, repeatability, and coverage.

Inner Logic's thesis is that many of those learning cycles can begin in virtual environments. The company says its platform can evaluate devices across thousands of virtual patients and procedures, giving developers a broader foundation for design iteration, model training, and failure analysis. Those capabilities are company-reported, but the overall direction aligns with a broader shift toward GPU-accelerated physics simulation, synthetic data, and digital twins.

That trend became more tangible on the same day as the financing announcement. NVIDIA introduced its open-source Medical Physics Simulation framework within Isaac for Healthcare and identified Inner Logic as a company using the framework to generate synthetic data, validate device mechanics, and produce in silico evidence intended to support regulatory pathways. The key word is support. Simulation can strengthen evidence generation, but it does not replace physical validation, regulatory review, or clinical proof.

The Team Behind the Thesis

Co-founder and CEO Tito Porras, MD, MBA, brings clinical training from a neurosurgery residency at Johns Hopkins Hospital. Co-founder and CTO Mathias Unberath, PhD is a Johns Hopkins computer science professor whose work spans computer-assisted medicine, computer vision, AI, and medical robotics. Co-founder and Chief Robotics Officer Axel Krieger, PhD is a Johns Hopkins mechanical engineering professor and director of the IMERSE Lab.

That combination is unusually well aligned with the company's technical challenge. Porras understands the clinical environment, Unberath specializes in perception and simulation, and Krieger has spent years advancing autonomous robotic systems. Inner Logic is not approaching procedural AI as another software category. It is treating it as a physical system whose intelligence must ultimately function inside real human anatomy.

The research foundation is substantial but requires careful interpretation. In 2022, Krieger's STAR system autonomously performed laparoscopic soft-tissue procedures on a pig. In 2025, a later Johns Hopkins robotic system completed a major phase of gallbladder removal on lifelike porcine tissue while adapting to unexpected conditions. Those achievements represent meaningful research milestones, not evidence that fully autonomous surgery is approved or ready for routine human care.

Why This Round Matters

The first opportunity is practical: enabling conventional device manufacturers to evaluate more designs across more virtual scenarios before building another prototype. A catheter does not need autonomous capabilities for simulation to uncover a mechanical weakness, and a heart valve does not require AI for virtual anatomy to improve design learning. That significantly expands the addressable market beyond next-generation robotic surgery.

The second opportunity is strategic. As procedural systems gain perception, planning, and decision-making capabilities, developers need simulation environments capable of testing behavior across situations that are rare, dangerous, or prohibitively expensive to recreate physically. The intelligence layer receives most of the attention, but the quality of the testing environment determines whether that intelligence deserves confidence.

The investor group reflects that intersection. General Catalyst brings deep healthcare experience, while Bison Ventures focuses on AI and deep technologies operating in the physical world. Bison already lists Semaphor among Caleb Appleton's current investments. Flare Capital also includes Semaphor in its portfolio as healthcare infrastructure, reinforcing the view that investors see the company as enabling infrastructure rather than another surgical robotics manufacturer.

What This Signals

Inner Logic is betting that procedural intelligence will evolve more like autonomous driving than traditional medical software. Better AI models matter, but progress accelerates when developers can evaluate more scenarios, reproduce failures, and compare outcomes before entering the most expensive phases of validation. The company's challenge is to make that simulation environment credible enough for medical-device teams operating within demanding engineering and regulatory constraints.

The risks are equally clear. Simulation must reflect clinical reality closely enough to produce reliable engineering decisions, and evidence generated in silico must connect convincingly with physical testing and regulatory expectations. An impressive virtual result that fails outside the simulation is not progress. It is simply a faster path to false confidence.

That is why the $11.5M seed round represents more than financing for another medical AI startup. It is a bet that the next generation of procedural technology will depend on the quality of the environment where devices learn, fail, and demonstrate credibility long before the consequences become human.